Recurrent Disease Terminated Phase 2 Trials for Sunitinib (DB01268)

IndicationStatusPhase
DBCOND0028541 (Recurrent Disease)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00408252Efficacy of SU 011248 in Head And Neck CarcinomaTreatment